NMN in the European Union
Legal or Not? Status as of 2026

β-Nicotinamide mononucleotide, more widely known as NMN, is a precursor of NAD+ — a molecule involved in cellular energy metabolism. This is precisely what drives the entire “longevity” and “cellular rejuvenation” marketing narrative that fuels demand. From a legal perspective, however, what matters is something else entirely: market popularity and legal status are two completely different things, and in the case of NMN they diverge particularly sharply.

A product that consumers actively seek out and can readily find in foreign online shops continues to operate in a legal grey area within the European Union.

Why NMN Qualifies as Novel Food

The starting point is Regulation (EU) 2015/2283 on novel food. Under its framework, any ingredient that was not consumed to a significant degree within the Union before 15 May 1997 requires prior authorisation before it can be lawfully placed on the market. NMN has no documented history of significant consumption in Europe before that date — and that is precisely why it qualifies as novel food. The consequence is unambiguous: until NMN has completed the full authorisation procedure, it may not lawfully be placed on the EU market, either as a food or as an ingredient in a food supplement.

Where We Stand Today: An EFSA Opinion Is Not a Marketing Authorisation

In May 2026, the European Food Safety Authority (EFSA) issued a positive safety opinion on synthetic β-NMN — based on an application submitted by EffePharm. The opinion considers an intake of up to 300 mg per day to be safe for adults, excluding pregnant and breastfeeding women, assessing NMN as a source of niacin (vitamin B3). The same opinion also addresses two related aspects — the safety of NMN as a novel food and its bioavailability as a source of nicotinamide in the context of Directive 2002/46/EC. For the industry, this is undoubtedly good news and a genuine step forward.

This is where the most common misunderstanding begins. A positive EFSA opinion is not a marketing authorisation. It is a scientific opinion — one stage of the procedure. For NMN to be lawfully placed on the market, a European Commission implementing act is required to add it to the EU novel food list, following a procedure involving the Member States. To date, no such act has been issued. This means that despite the positive scientific assessment, NMN still cannot formally be placed lawfully on the EU market. In legal terms, “almost authorised” still means “not authorised”.

flowchart LR
    A[Wniosek\nwnioskodawcy] --> B[Ocena EFSA]
    B --> C[Pozytywna opinia\nbezpieczenstwa]
    C --> D[Procedura z udzialem\npanstw czlonkowskich]
    D --> E[Akt wykonawczy\nKomisji Europejskiej]
    E --> F[Wpis na Unijng\nListe Nowej Zywnosci]
    F --> G[Legalna sprzedaz\nna rynku UE]
    style C fill:#0f766e,stroke:#14b8a6,color:#e2e8f0
    style D fill:#1e293b,stroke:#f59e0b,color:#fbbf24
    style E fill:#1e293b,stroke:#64748b,color:#94a3b8
    style F fill:#1e293b,stroke:#64748b,color:#94a3b8
    style G fill:#1e293b,stroke:#64748b,color:#94a3b8

The Trap: Applicant-Specific Authorisation

This is the most important element of the entire picture, and simultaneously the one most frequently overlooked. Novel food authorisation does not generally apply to an ingredient “in the abstract”, as a notional substance. It applies to a specific product, with a defined specification, originating from a specific manufacturer and produced in a defined manner. Moreover, the applicant who bore the cost of the studies and dossier may obtain five years of data protection — effectively granting exclusivity over the novel food as so defined.

The practical implications are very concrete. Even once NMN is formally authorised, the applicant will be the first — and for a period potentially the only — party to benefit from that authorisation. An importer bringing in NMN from a different source, for example a popular Japanese product, may still have no legal basis for selling it, even though “NMN is already authorised in the EU”. It is no coincidence that even now only the applicant can communicate the positive EFSA opinion, while all other NMN producers remain subject to the restrictions of the novel food regime.

flowchart TD
    A[Czy moj NMN jest\nlegalny do sprzedazy w UE?] --> B{Czy NMN figuruje\nna Unijnej Liscie\nNowej Zywnosci?}
    B -->|Nie| C[STOP: sprzedaz\nnielegalna]
    B -->|Tak| D{Czy autoryzacja\nobejmuje moje zrodlo\ni specyfikacje?}
    D -->|Nie| E{Czy uplyngl okres\nochrony danych\n5 lat?}
    D -->|Tak| F[Mozesz sprzedawac\nzgodnie z warunkami\nautoryzacji]
    E -->|Nie| G[STOP: wylgcznosc\nwnioskodawcy\nblokuje sprzedaz]
    E -->|Tak| H{Czy Twoj NMN\nspelnia specyfikacje\nz Listy Unijnej?}
    H -->|Tak| I[Mozesz sprzedawac\npo weryfikacji\nzgodnosci]
    H -->|Nie| J[STOP: wymaga\nwlasnej autoryzacji]
    style C fill:#7f1d1d,stroke:#f87171,color:#fecaca
    style G fill:#7f1d1d,stroke:#f87171,color:#fecaca
    style J fill:#7f1d1d,stroke:#f87171,color:#fecaca
    style F fill:#064e3b,stroke:#10b981,color:#d1fae5
    style I fill:#064e3b,stroke:#10b981,color:#d1fae5

The Grey Market and Enforcement Realities

For years, NMN has been and continues to be sold within the Union through grey-market channels — until national supervisory authorities begin enforcing the novel food classification. It is worth recalling the principle from general food law: responsibility for product compliance rests with the business operator active in the EU, typically the importer or distributor. It is that operator who bears the risk of a market withdrawal order, a sales ban, or administrative sanctions. The mere fact that a product can physically be purchased from an online shop in no way determines its legality — and provides no line of defence before a regulatory authority.

NMN in the USA and Asia — Why Products Exist There Despite Being Problematic in the EU

The divergence between markets is a frequent source of false reassurance. In the United States, the FDA reversed its earlier position in September 2025 and confirmed that NMN is not excluded from the definition of a dietary supplement. In Japan and parts of Asia, NMN has been freely available for years. This explains why so many Japanese and American NMN products are present on the market. The crucial point, however, is that legal status in the country of origin does not transfer to the European Union — legality in Tokyo or the USA creates no basis for selling the product in Warsaw or Berlin.

What This Means in Practice

For anyone considering placing an NMN product on the EU market, prudence suggests several things. First — do not treat the EFSA opinion as a green light; what is needed is a Commission implementing act and an entry on the EU novel food list. Second — once authorisation is in place, verify whether it specifically covers the source and specification of NMN you intend to import, and whether it is protected by the applicant's data exclusivity. Third — monitor the status of the procedure on an ongoing basis, as the situation in this area changes from quarter to quarter. Finally, the question of claims: even after authorisation, the strict rules of Regulation (EC) No 1924/2006 will apply, which absolutely prohibit attributing to food the properties of treating or preventing disease — the entire anti-ageing narrative in its medical dimension will remain impermissible, and if NMN is authorised as a source of niacin, only authorised health claims relating to niacin will be available.

Conclusions

NMN is a textbook example of the gap between market demand and the state of the law. The direction is positive — the EFSA opinion genuinely brings authorisation closer — but between “safe according to EFSA” and “lawful to sell in my product” there remains a considerable distance, along which the applicant-specific authorisation mechanism plays the most important role. A business operator who treats the positive opinion as a signal to launch may be in for a serious disappointment. One who treats it as a signal that the market is opening and checks the status of their specific source in good time has a genuine chance of entering the market knowingly and in compliance with the law.

Disclaimer: Tomasz Krawczyk — legal counsel, specialising in EU and Polish food law and food supplements law. supplemental.pl · foodlaw.ai. This material is for general information purposes only and reflects the position as of 2026; it does not constitute legal advice in any individual matter. The regulatory status of NMN is evolving rapidly — the current position should be verified before taking any business decisions.